Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jimmy Couch

Neurology Paducah, KY Doctor of Osteopathy

NPI 1932281904 CMS profile 224235

1532 Lone Oak Rd, Suite 143, Paducah, KY 42003

Open in the dashboard

General payments

$8,145

460 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jimmy Couch of Paducah, KY is reported in the CMS Open Payments database as having received $8,145 across 460 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $83 4
2024 General $60 3
2023 General $1,724 103
2022 General $1,265 104
2021 General $922 83
2020 General $3,142 86
2019 General $948 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jimmy Couch
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jimmy Couch were reported at $83. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jimmy Couch Neurology median Middle half National median
2019 $948 $474 $118–$2,177 $163
2020 $3,142 $367 $82–$2,309 $114
2021 $922 $438 $104–$2,547 $132
2022 $1,265 $442 $103–$2,388 $149
2023 $1,724 $464 $119–$2,312 $160
2024 $60 $468 $119–$2,323 $164
2025 $83 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LivaNova USA, Inc. $2,014 8 payments
  2. AbbVie, Inc. $1,358 114 payments
  3. Allergan Inc. $993 74 payments
  4. Supernus Pharmaceuticals, Inc. $515 35 payments
  5. Pfizer Inc. $331 20 payments
  6. Novartis Pharmaceuticals Corporation $254 20 payments
  7. Alexion Pharmaceuticals, Inc. $233 9 payments
  8. Sunovion Pharmaceuticals Inc. $212 23 payments
  9. EMD Serono, Inc. $191 20 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $175 25 payments
  11. Other $1,869 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,827 453 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,107 4 payments
  3. Education $210 3 payments
Products named General payments · program years 2019–2025
  1. VNS Therapy $1,989 7 payments
  2. UBRELVY Neuroscience $660 64 payments
  3. BOTOX Hyperhydrosis $636 52 payments
  4. QULIPTA $455 37 payments
  5. OXTELLAR XR $452 30 payments
  6. UBRELVY Neuroscience $343 21 payments
  7. NURTEC ODT Primary Care $225 28 payments
  8. NURTEC ODT Pain $221 18 payments
  9. APTIOM $195 23 payments
  10. BOTOX Neuroscience $173 8 payments
  11. Other $2,890 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

2,892

Median for Neurology: 833

Drug cost

$513,208

Median for Neurology: $202,670

Branded share of claims

24.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex (4 Pack) Interferon Beta-1a Brand 13 $105,737
Ubrelvy Ubrogepant Brand 49 $64,490
Banzel Rufinamide Brand 11 $51,433
Epidiolex Cannabidiol (Cbd) Brand 17 $43,476
Aimovig Autoinjector Erenumab-Aooe Brand 43 $32,116
Vimpat Lacosamide Brand 17 $31,469
Qulipta Atogepant Brand 26 $27,811
Lacosamide Generic 152 $22,935
Aptiom Eslicarbazepine Acetate Brand 12 $15,335
Levetiracetam Generic 311 $13,787

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$76,481

Medicare's payments for the services billed

Medicare patients

383

Average age 69

Services billed

1,093

202 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Depression 46%
Ischemic heart disease 34%
Chronic kidney disease 34%
Diabetes 32%
COPD 23%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record